Keynote 224 Resultset. Had previously been treated with sorafenib and were either intolerant to this treatment or showed radiographic progression. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on treatment with sorafenib, so [pembrolizumab.
Patients were required to have disease progression on or. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on treatment with sorafenib, so [pembrolizumab.
